Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in Patients With End-Stage Kidney Disease on Hemodialysis

John Havill  
Kidney Specialists of Southern Nevada, Las Vegas, NV

Nelson Kopyt DO, FASN, FACP  
Lehigh Valley Health Network, Nelson.Kopyt@lvhn.org

Daniel Coyne  
Washington University, St Louis, MO

Michael Weiswasser  
Celgene Corporation, Warren, NJ

William T. Smith  
Celgene Corporation, Warren, NJ

Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine

Part of the Medical Sciences Commons, and the Nephrology Commons

Published In/Presented At  

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.
INTRODUCTION

Sotatercept SC 0.7 mg/kg for up to 8 doses* unless rescued or discontinued early

All randomized subjects will continue with sotatercept 0.3 mg/kg or placebo to evaluate PK and safety.

Subjects (%)

Placebo Sotatercept Placebo Sotatercept 0.3 mg/kg Sotatercept 0.5 mg/kg Sotatercept 0.7 mg/kg Sotatercept 0.7/0.4 mg/kg

Figure 1. Proportion of Subjects (N=11) with Improvement in Trabecular BMD

Figure 4. Proportion of Subjects (N=11) with Improvement in Trabecular BMD

CONCLUSIONS

Placebo (n ~3)

Sotatercept 0.3 mg/kg

Sotatercept 0.5 mg/kg

Sotatercept 0.7 mg/kg

Sotatercept 0.7/0.4 mg/kg

Placebo SC 0.3 mg/kg

Sotatercept SC 0.5 mg/kg

Sotatercept SC 0.7 mg/kg

Sotatercept SC 0.7/0.4 mg/kg

Figure 3. Proportion of Subjects (N=11) with Response to Treatment (Placebo Only)